Cambridge Investment Research Advisors, Inc. Bridge Bio Pharma, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 15,263 shares of BBIO stock, worth $443,848. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,263Holding current value
$443,848% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$735 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$731 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$413 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$362 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$176 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.31B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...